PTU - Polskie Towarzystwo Urologiczne
list of articles:

Cytotoxic activity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) against bladder cancer cells after using chemotherapeutic drugs
Article published in Urologia Polska 2007/60/2.


Ewelina Szliszka, Anatol Majcher, Maciej Domino, Grażyna Pietsz, Wojciech Król
Katedra i Zakład Mikrobiologii i Immunologii w Zabrzu Śląskiej Akademii Medycznej w Katowicach


urinary bladder, bladder cancer, TRAIL, chemotherapeutic drugs


Introduction. Transitional cell carcinoma (TCC) of the bladder is a common malignancy. The majority of bladder tumors are superficial at diagnosis and, after local surgical therapy, have a high rate of local recurrence and progression. Current treatments extend the time of recurrence but do not alter disease survival rate. Tumor necrosis factor related apoptosis in-ducing ligand (TRAIL) belongs to the tumor necrosis factor superfamily and it selectively induces apoptosis in cancer cells, with no toxicity against normal tissues.
The aim of the study. TRAIL is one of the most promising candidates for cancer therapy. In this study, we investigated the effect of TRAIL on bladder cancer cells with or without che-motherapeutic drugs pretreatment.
Material and methods. Human transitional bladder cancer cell line SW780 was tested for TRAIL sensitivity in the presence or absence of the chemotherapeutic agents: doxorubicin, epirubicin, gemcitabine and mitomycin C. Cytotoxicity was determined by MTT and LDH assays.
Results. We reported that chemotherapeutic agents significantly augmented TRAIL mediated cytotoxicity against transitional bladder cancer cells. The most potent cytotoxic effect in com-bination with TRAIL was exhibited by doxorubicin (85,9 +/-1,0 % killing).
Conclusion. The increase of cytotoxic effect of TRAIL after application of low dose chemo-therapeutic agent in bladder cancer cells was observed. This study demonstrated that TRAIL treatment combined with chemotherapy may provide the basis for a new therapeutic approach to induce apoptosis in bladder cancer cells and decrease the dose of chemotherapeutic drugs.


  1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer Statistics. CA Cancer J Clin 1999, 49, 8-31.
  2. Didkowska J, Wojciechowska U, Tarnowski W, Zatoński W: Nowotwory złośliwe w Polsce w 1999. Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie. Zakład Epidemiologii i Prewencji Nowotworów. Warszawa, 2002, 15-37.
  3. Oesterlinck W, Lobel B, Jakse G: Guidelines on bladder cancer. Eur Urol 2004, 41, 105-112.
  4. Ashkenazi A, Pai R, Fong S et al: Safety and antitumor activity of recombinant Apo2 ligand. J Clin Invest 1999, 104, 155-162.
  5. Kelley SK, Harris LA, Xie D et al: Pre-clinical studies to predict the disposition of Apo2L. tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol Exp Ther 2001, 299, 31-38.
  6. Almasan A, Ashkenazi A: Apo2L. TRAIL: apoptosis signaling, biology and potential for cancer therapy. Cytokine Growth Factor Rev 2003, 14, 337-348.
  7. Yagita H, Takeda K, Hayakawa Y: TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004, 95, 777-783.
  8. Zhang L, Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005, 12, 228-227.
  9. Shankar S, Srivastava RK: Enhancement oh therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 2004, 7, 139-156.
  10. Wu XX, Ogawa O, Kaleki Y: TRAIL and chemotherapeutic drugs in cancer therapy. Vitam Horm 2004, 67, 365-583.
  11. Donat SM: Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am 2003, 30, 765-776.
  12. Kyriazis AA, Kyriazis AP, McCombs WB, Peterson WD: Morphological, biological and biochemical characteristics oh human bladder transitional cell carcinomas grown in tissues culture and in nude mice. Cancer Res 1984, 44, 3397-4005.
  13. Cell proliferation kit I (MTT). Instruction manual. Version 3. Roche Applied Science, Germany, 2003.
  14. Cytotoxicity detection kit (LDH). Instruction manual. Version 5. Roche Applied Science, Germany, 2004.
  15. Schenkman E, Lamm DL: Superficial bladder cancer therapy. Scientific World Journal 2004, 28, 387-399.
  16. Pieras E, Palou J, Salvador J et al: Menagement and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation. Eur Urol 2003, 44, 222-225.
  17. Kołodziej A, Dembowski J: Chemioterapia dopęcherzowa w leczeniu powierzchownego raka pęcherza moczowego. Urol Pol 2002, 59, 9-14.
  18. El-Zawahry AM, McKillop J, Voelkel-Johnson C: Doxorubicin increases the effectiveness of Apo2L. TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer 2005, 7, 2-5.
  19. Kelly MM, Hoel BD, Voelkel-Johnson C: Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis witch correlates with the loss of c-FLIP expression. Cancer Biol Ther 2002, 5, 520-527.
  20. Kang J, Bu J, Hao Y, Chen F: Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cell line LNCaP. Prostate Cancer Prostatic Dis 2005, 8, 274-279.
  21. Wu XX, Kakehi Y, Mizutani Y et al: Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Int. Oncol 2004, 20, 949-954.
  22. Wu XX, Kakehi Y, Mizutani Y et al: Enhancement of TRAIL. Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int J Cancer 2003, 104, 409-417.
  23. Wu XX, Ogawa O, Kaleki Y: Sensitization of human renal cell carcinoma cell lines to TRAIL-induced apoptosis by anthracyclines. Int J Urol 2004, 11, 164-170.
  24. Zisman A, Ng CP, Pantuck AJ: Actionomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to APO2L. TRAIL-mediated apoptosis. J Immunother 2001, 24, 459-471.
  25. Xu ZW, Kleeff J, Friess H et al: Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Res 2003, 23, 251-258.
  26. Hylander BL, Pitoniak R, Penetrante RB et al: The antitumor effect of APO2L. TRAIL on patient pancreatic adenocarcinoma grown as xenografts in SCID mice. J Transl Med 2005, 3, 22.
  27. Zu H, Zhang L, Huang X et al: Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain I through distinct mechanisms. Mol Ther 2004, 9, 666-673.
  28. Mizutani Y, Nakao M, Ogawa O: Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. J Urol 2001, 165, 263-270.


Ewelina Szliszka
Katedra i Zakład Mikrobiologii i Immunologii
41-808 Zabrze
ul. Jordana 19
tel. (032) 272 25 54